We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RECEF market cap is 122.37M. The company's latest EPS is AUD -0.0866 and P/E is -5.43.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 1.12M | 1.86M | 3.09M | 4.37M | 5.03M |
| Operating Income | -4.29M | -13.61M | -11.06M | -12.96M | -17.02M |
| Net Income | -4.32M | -13.51M | -10.99M | -13.08M | -17.66M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 3.24M | 21.68M | 12.62M | 2.56M | 6.37M |
| Total Liabilities | 931k | 1.18M | 2.56M | 5.15M | 15.89M |
| Total Equity | 2.31M | 20.5M | 10.06M | -2.59M | -9.52M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -3.81M | -7.86M | -9.01M | -12.69M | -13.01M |
| Investing | -6k | -76k | -40k | -39k | -142k |
| Financing | 6.09M | 26.12M | -240k | 2.71M | 16.01M |
| Market Cap | 122.37M |
| Price to Earnings Ratio | -5.43 |
| Price to Sales Ratio | 19.03 |
| Price to Cash Ratio | 21.76 |
| Price to Book Ratio | -10.06 |
| Dividend Yield | - |
| Shares Outstanding | 203.95M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 9.09% |
| 52 Week High | 0.60 |
| 52 Week Low | 0.55 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Recce Pharmaceuticals (PK) |
| Address |
suite 10 perth, western australia 2000 |
| Website | https://www.recce.com.au |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
